Global Hepatic Antiviral Drug Market Research Report 2022
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatic Antiviral Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Hepatic Antiviral Drug Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Homecare
1.3.4 Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hepatic Antiviral Drug Market Perspective (2017-2028)
2.2 Hepatic Antiviral Drug Growth Trends by Region
2.2.1 Hepatic Antiviral Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Hepatic Antiviral Drug Historic Market Size by Region (2017-2022)
2.2.3 Hepatic Antiviral Drug Forecasted Market Size by Region (2023-2028)
2.3 Hepatic Antiviral Drug Market Dynamics
2.3.1 Hepatic Antiviral Drug Industry Trends
2.3.2 Hepatic Antiviral Drug Market Drivers
2.3.3 Hepatic Antiviral Drug Market Challenges
2.3.4 Hepatic Antiviral Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatic Antiviral Drug Players by Revenue
3.1.1 Global Top Hepatic Antiviral Drug Players by Revenue (2017-2022)
3.1.2 Global Hepatic Antiviral Drug Revenue Market Share by Players (2017-2022)
3.2 Global Hepatic Antiviral Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatic Antiviral Drug Revenue
3.4 Global Hepatic Antiviral Drug Market Concentration Ratio
3.4.1 Global Hepatic Antiviral Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatic Antiviral Drug Revenue in 2021
3.5 Hepatic Antiviral Drug Key Players Head office and Area Served
3.6 Key Players Hepatic Antiviral Drug Product Solution and Service
3.7 Date of Enter into Hepatic Antiviral Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatic Antiviral Drug Breakdown Data by Type
4.1 Global Hepatic Antiviral Drug Historic Market Size by Type (2017-2022)
4.2 Global Hepatic Antiviral Drug Forecasted Market Size by Type (2023-2028)
5 Hepatic Antiviral Drug Breakdown Data by Application
5.1 Global Hepatic Antiviral Drug Historic Market Size by Application (2017-2022)
5.2 Global Hepatic Antiviral Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Hepatic Antiviral Drug Market Size (2017-2028)
6.2 North America Hepatic Antiviral Drug Market Size by Country (2017-2022)
6.3 North America Hepatic Antiviral Drug Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Hepatic Antiviral Drug Market Size (2017-2028)
7.2 Europe Hepatic Antiviral Drug Market Size by Country (2017-2022)
7.3 Europe Hepatic Antiviral Drug Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hepatic Antiviral Drug Market Size (2017-2028)
8.2 Asia-Pacific Hepatic Antiviral Drug Market Size by Country (2017-2022)
8.3 Asia-Pacific Hepatic Antiviral Drug Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Hepatic Antiviral Drug Market Size (2017-2028)
9.2 Latin America Hepatic Antiviral Drug Market Size by Country (2017-2022)
9.3 Latin America Hepatic Antiviral Drug Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatic Antiviral Drug Market Size (2017-2028)
10.2 Middle East & Africa Hepatic Antiviral Drug Market Size by Country (2017-2022)
10.3 Middle East & Africa Hepatic Antiviral Drug Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Teva Pharmaceutical Industries
11.1.1 Teva Pharmaceutical Industries Company Detail
11.1.2 Teva Pharmaceutical Industries Business Overview
11.1.3 Teva Pharmaceutical Industries Hepatic Antiviral Drug Introduction
11.1.4 Teva Pharmaceutical Industries Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.1.5 Teva Pharmaceutical Industries Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Hepatic Antiviral Drug Introduction
11.2.4 Bristol-Myers Squibb Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Hepatic Antiviral Drug Introduction
11.3.4 Zydus Cadila Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.3.5 Zydus Cadila Recent Development
11.4 Cipla
11.4.1 Cipla Company Detail
11.4.2 Cipla Business Overview
11.4.3 Cipla Hepatic Antiviral Drug Introduction
11.4.4 Cipla Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.4.5 Cipla Recent Development
11.5 Prinston Pharmaceutical
11.5.1 Prinston Pharmaceutical Company Detail
11.5.2 Prinston Pharmaceutical Business Overview
11.5.3 Prinston Pharmaceutical Hepatic Antiviral Drug Introduction
11.5.4 Prinston Pharmaceutical Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.5.5 Prinston Pharmaceutical Recent Development
11.6 Hetero Drug
11.6.1 Hetero Drug Company Detail
11.6.2 Hetero Drug Business Overview
11.6.3 Hetero Drug Hepatic Antiviral Drug Introduction
11.6.4 Hetero Drug Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.6.5 Hetero Drug Recent Development
11.7 Aurobindo Pharma
11.7.1 Aurobindo Pharma Company Detail
11.7.2 Aurobindo Pharma Business Overview
11.7.3 Aurobindo Pharma Hepatic Antiviral Drug Introduction
11.7.4 Aurobindo Pharma Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.7.5 Aurobindo Pharma Recent Development
11.8 Apotex
11.8.1 Apotex Company Detail
11.8.2 Apotex Business Overview
11.8.3 Apotex Hepatic Antiviral Drug Introduction
11.8.4 Apotex Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.8.5 Apotex Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Detail
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Hepatic Antiviral Drug Introduction
11.9.4 Gilead Sciences Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.9.5 Gilead Sciences Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Hepatic Antiviral Drug Introduction
11.10.4 Mylan Revenue in Hepatic Antiviral Drug Business (2017-2022)
11.10.5 Mylan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesTable 1. Global Hepatic Antiviral Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Entecavir
Table 3. Key Players of Tenofovir
Table 4. Key Players of lamivudine
Table 5. Key Players of Adefovir
Table 6. Key Players of Telbivudine
Table 7. Key Players of Others
Table 8. Global Hepatic Antiviral Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Hepatic Antiviral Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global Hepatic Antiviral Drug Market Size by Region (2017-2022) & (US$ Million)
Table 11. Global Hepatic Antiviral Drug Market Share by Region (2017-2022)
Table 12. Global Hepatic Antiviral Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 13. Global Hepatic Antiviral Drug Market Share by Region (2023-2028)
Table 14. Hepatic Antiviral Drug Market Trends
Table 15. Hepatic Antiviral Drug Market Drivers
Table 16. Hepatic Antiviral Drug Market Challenges
Table 17. Hepatic Antiviral Drug Market Restraints
Table 18. Global Hepatic Antiviral Drug Revenue by Players (2017-2022) & (US$ Million)
Table 19. Global Hepatic Antiviral Drug Market Share by Players (2017-2022)
Table 20. Global Top Hepatic Antiviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatic Antiviral Drug as of 2021)
Table 21. Ranking of Global Top Hepatic Antiviral Drug Companies by Revenue (US$ Million) in 2021
Table 22. Global 5 Largest Players Market Share by Hepatic Antiviral Drug Revenue (CR5 and HHI) & (2017-2022)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hepatic Antiviral Drug Product Solution and Service
Table 25. Date of Enter into Hepatic Antiviral Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hepatic Antiviral Drug Market Size by Type (2017-2022) & (US$ Million)
Table 28. Global Hepatic Antiviral Drug Revenue Market Share by Type (2017-2022)
Table 29. Global Hepatic Antiviral Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 30. Global Hepatic Antiviral Drug Revenue Market Share by Type (2023-2028)
Table 31. Global Hepatic Antiviral Drug Market Size by Application (2017-2022) & (US$ Million)
Table 32. Global Hepatic Antiviral Drug Revenue Market Share by Application (2017-2022)
Table 33. Global Hepatic Antiviral Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 34. Global Hepatic Antiviral Drug Revenue Market Share by Application (2023-2028)
Table 35. North America Hepatic Antiviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Hepatic Antiviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Hepatic Antiviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 38. Europe Hepatic Antiviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 39. Asia-Pacific Hepatic Antiviral Drug Market Size by Region (2017-2022) & (US$ Million)
Table 40. Asia-Pacific Hepatic Antiviral Drug Market Size by Region (2023-2028) & (US$ Million)
Table 41. Latin America Hepatic Antiviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 42. Latin America Hepatic Antiviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 43. Middle East & Africa Hepatic Antiviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 44. Middle East & Africa Hepatic Antiviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 45. Teva Pharmaceutical Industries Company Detail
Table 46. Teva Pharmaceutical Industries Business Overview
Table 47. Teva Pharmaceutical Industries Hepatic Antiviral Drug Product
Table 48. Teva Pharmaceutical Industries Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 49. Teva Pharmaceutical Industries Recent Development
Table 50. Bristol-Myers Squibb Company Detail
Table 51. Bristol-Myers Squibb Business Overview
Table 52. Bristol-Myers Squibb Hepatic Antiviral Drug Product
Table 53. Bristol-Myers Squibb Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 54. Bristol-Myers Squibb Recent Development
Table 55. Zydus Cadila Company Detail
Table 56. Zydus Cadila Business Overview
Table 57. Zydus Cadila Hepatic Antiviral Drug Product
Table 58. Zydus Cadila Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 59. Zydus Cadila Recent Development
Table 60. Cipla Company Detail
Table 61. Cipla Business Overview
Table 62. Cipla Hepatic Antiviral Drug Product
Table 63. Cipla Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 64. Cipla Recent Development
Table 65. Prinston Pharmaceutical Company Detail
Table 66. Prinston Pharmaceutical Business Overview
Table 67. Prinston Pharmaceutical Hepatic Antiviral Drug Product
Table 68. Prinston Pharmaceutical Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 69. Prinston Pharmaceutical Recent Development
Table 70. Hetero Drug Company Detail
Table 71. Hetero Drug Business Overview
Table 72. Hetero Drug Hepatic Antiviral Drug Product
Table 73. Hetero Drug Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 74. Hetero Drug Recent Development
Table 75. Aurobindo Pharma Company Detail
Table 76. Aurobindo Pharma Business Overview
Table 77. Aurobindo Pharma Hepatic Antiviral Drug Product
Table 78. Aurobindo Pharma Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 79. Aurobindo Pharma Recent Development
Table 80. Apotex Company Detail
Table 81. Apotex Business Overview
Table 82. Apotex Hepatic Antiviral Drug Product
Table 83. Apotex Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 84. Apotex Recent Development
Table 85. Gilead Sciences Company Detail
Table 86. Gilead Sciences Business Overview
Table 87. Gilead Sciences Hepatic Antiviral Drug Product
Table 88. Gilead Sciences Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 89. Gilead Sciences Recent Development
Table 90. Mylan Company Detail
Table 91. Mylan Business Overview
Table 92. Mylan Hepatic Antiviral Drug Product
Table 93. Mylan Revenue in Hepatic Antiviral Drug Business (2017-2022) & (US$ Million)
Table 94. Mylan Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of FiguresFigure 1. Global Hepatic Antiviral Drug Market Share by Type: 2021 VS 2028
Figure 2. Entecavir Features
Figure 3. Tenofovir Features
Figure 4. lamivudine Features
Figure 5. Adefovir Features
Figure 6. Telbivudine Features
Figure 7. Others Features
Figure 8. Global Hepatic Antiviral Drug Market Share by Application in 2021 & 2028
Figure 9. Hospitals Case Studies
Figure 10. Homecare Case Studies
Figure 11. Clinics Case Studies
Figure 12. Others Case Studies
Figure 13. Hepatic Antiviral Drug Report Years Considered
Figure 14. Global Hepatic Antiviral Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 15. Global Hepatic Antiviral Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Hepatic Antiviral Drug Market Share by Region: 2021 VS 2028
Figure 17. Global Hepatic Antiviral Drug Market Share by Players in 2021
Figure 18. Global Top Hepatic Antiviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatic Antiviral Drug as of 2021)
Figure 19. The Top 10 and 5 Players Market Share by Hepatic Antiviral Drug Revenue in 2021
Figure 20. North America Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. North America Hepatic Antiviral Drug Market Share by Country (2017-2028)
Figure 22. United States Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Hepatic Antiviral Drug Market Share by Country (2017-2028)
Figure 26. Germany Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Hepatic Antiviral Drug Market Share by Region (2017-2028)
Figure 34. China Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Japan Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. South Korea Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Southeast Asia Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. India Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Australia Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Hepatic Antiviral Drug Market Share by Country (2017-2028)
Figure 42. Mexico Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Brazil Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Hepatic Antiviral Drug Market Share by Country (2017-2028)
Figure 46. Turkey Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Saudi Arabia Hepatic Antiviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Teva Pharmaceutical Industries Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 50. Zydus Cadila Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 51. Cipla Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 52. Prinston Pharmaceutical Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 53. Hetero Drug Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 54. Aurobindo Pharma Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 55. Apotex Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 56. Gilead Sciences Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 57. Mylan Revenue Growth Rate in Hepatic Antiviral Drug Business (2017-2022)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed